留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice

Meng-Li Wu Feng-Liang Liu Jing Sun Xin Li Jian-Ru Qin Qi-Hong Yan Xia Jin Xin-Wen Chen Yong-Tang Zheng Jin-Cun Zhao Jian-Hua Wang

Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Jian-Ru Qin, Qi-Hong Yan, Xia Jin, Xin-Wen Chen, Yong-Tang Zheng, Jin-Cun Zhao, Jian-Hua Wang. Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice. Zoological Research, 2022, 43(3): 457-468. doi: 10.24272/j.issn.2095-8137.2021.469
Citation: Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Jian-Ru Qin, Qi-Hong Yan, Xia Jin, Xin-Wen Chen, Yong-Tang Zheng, Jin-Cun Zhao, Jian-Hua Wang. Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice. Zoological Research, 2022, 43(3): 457-468. doi: 10.24272/j.issn.2095-8137.2021.469

抗组胺药物和瑞德西韦联用可同时抑制新型冠状病毒复制和缓解炎症造成的小鼠肺部损伤

doi: 10.24272/j.issn.2095-8137.2021.469

Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice

Funds: This work was supported by the National Natural Science Foundation of China (82172242, 81873965), State Key Laboratory of Respiratory Disease, Guangzhou, China (SKLRD-OP-202207), National Key R&D Program of China (2020YFC0842000), Natural Science Foundation of Guangdong (2022A1515012053), and Key Project from the Chinese Academy of Sciences (QYZDB-SSW-SMC059)
More Information
  • 摘要: 新冠肺炎(COVID-19)是由新型冠状病毒(SARS-CoV-2)感染导致的炎症相关疾病。抗病毒药物和抗炎药物联用有望在临床治疗取得有益的效果。我们最近证明,肥大细胞(Mast cell,MC)是SARS-CoV-2引发炎症的重要效应细胞。发现SARS-CoV-2刺突蛋白(Spike)通过诱导MC脱颗粒诱发肺泡上皮细胞炎症从而造成组织通透性破坏,并发现临床上治疗过敏性疾病的抗组胺药物可作为MC稳定剂,阻止Spike诱导的MC脱颗粒,进而抑制炎症发生和保护肺损伤。在该研究中,我们进一步阐述MC在SARS-CoV-2引发肺损伤中的作用,并评价抗组胺药物和抗病毒药物联用对病毒复制和炎症损伤的双重抑制效果。证明Spike诱导的MC脱颗粒可导致肺泡毛细血管损伤,而抗组胺药物预处理肺微血管内皮细胞,可防止细胞间紧密连接的破坏;特别重要一点,发现抗组胺药物HR1(histamine receptor)拮抗剂氯雷他定(Loratadine)和抗病毒药物瑞德西韦(Remdesivir)联用,可同时抑制SARS-CoV-2复制和缓解炎症造成的小鼠肺部损伤。该研究再次证明了MC在SARS-CoV-2诱导肺部炎症和导致肺损伤中的重要作用,并提出一种COVID-19抗病毒药物和抗炎药物联用治疗策略。
    #Authors contributed equally to this work
  • Figure  1.  MC degranulation disrupts VE-cadherin in HULEC-5a cells

    A–C: VE-cadherin expression observed by fluorescence microscopy. HULEC-5a cells (1×105) were seeded on a coverslip to form a monolayer, then treated with RBD-stimulated LAD2 cell culture supernatant (Deg. Supern.) (300 μL), or Medium (A) with RBD protein (2 μg/mL), or co-cultured with LAD2 cells (1×105) with or without RBD protein (B) for 48 h. In some groupss, Lor. (2.5 μg/mL), Eba. (1.5 μg/mL), or Ket. (4 μg/mL) was used to pretreat HULEC-5a cells for 2 h before stimulation (C). VE-cadherin was stained with specific antibodies and observed via fluorescence microscopy. Nucleus was stained with DAPI. Scale bar: 20 μm. D, E: VE-cadherin expression detected by flow cytometry. Cultured HULEC-5a cells were treated and immunostained as above, and VE-cadherin expression was detected by flow cytometry. Mean fluorescence intensity (MFI) was calculated. F, G: Spike/RBD-triggered MC activation for degranulation. LAD2 cells (3×105) were incubated with spike/RBD (2 μg/mL) at 37 °C for 1 h, fixed with 4% paraformaldehyde, permeabilized, immunostained with anti-avidin-FITC at 4 °C for 1 h, then analyzed by flow cytometry (F). Released histamines in cell culture supernatants were quantified by ELISA (G). Representative data are from four independent repeats.

    Figure  2.  MC degranulation induces inflammation in human microvascular endothelial cells

    HULEC-5a cells were stimulated with RBD-treated LAD2 cell culture supernatants for 24 h. Total RNA was extracted, and transcriptome analysis was performed. A: Volcano plot of DEGs comparing LAD2/RBD supernatant-treated versus medium-treated groups. Symbols of up-regulated and down-regulated genes are shown. B: GO functional enrichment analysis of DEGs. Color bar indicates minus logarithm of q values, and bubble size indicates absolute gene counts enriched in GO terms. C: GSEA of distribution of gene sets related to inflammatory response and enrichment scores based on DEGs. D: Heatmaps showing relative expression level (left panel), fold-change (middle panel), and adjusted P-values (right panel) for cytokine/chemokine-related genes. E: Pretreatment with antihistamines blocks expression of pro-inflammatory factors. HULEC-5a cells were pretreated with Lor. (2.5 μg/mL), Eba. (1.5 μg/mL), or Ket. (4 μg/mL) for 2 h before stimulation. Cellular mRNA levels of S100A9, CXCL11, CCL7, CXCL10, IL-6, and ICAM-1 were quantified by qRT-PCR and normalized to gapdh mRNA. Representative data are from four independent repeats. F, G: IL-6 expression was detected by intracellular staining and flow cytometry. Three independent repeats are shown, MFI: Mean fluorescence intensity (G). Data are mean±standard deviation (SD). ***: P<0.001 indicates significant differences.

    Figure  3.  Combined remdesivir and Lor. treatment dampens SARS-CoV-2 replication and inflammation

    A: Illustration of mouse treatments. BALB/c mice were infected intranasally with SARS-CoV-2 501Y.V2 strain (7.1×104 CCID50). In some mice, Lor. (10 mg/kg) was administered (i.p.) 1 day before infection, then given each day over the course of infection; remdesivir (25 mg/kg) was administered (i.p.) at the time of infection and used once daily until euthanasia. Each treatment group contained five mice; three mice without infection or drug treatment were used as mock controls. Lungs were collected at 3 dpi. B: Body weight was monitored. Mice were euthanized and lung lobes were harvested for analysis. C: Viral replication was monitored by quantifying expression of nucleocapsid gene. D: mRNA levels of IL-6, TNF-α, CCL5, CXCL11, CCL20, and ICMA-1 were quantified using qRT-PCR and normalized to gapdh mRNA. E: Frozen lung sections were immunostained with VE-cadherin to indicate pulmonary microvascular integrity. Nucleus was stained with DAPI. Scale bar: 50 μm. Data are mean±SD. *: P<0.05; **: P<0.01; ***: P<0.001.

    Figure  4.  Combined remdesivir and Lor. treatment reduces lung lesions in SARS-CoV-2-infected mice

    Lungs from above treated BALB/c mice were collected at 3 dpi. A: Pathological lung sections with H&E staining. Scale bar: 100 μm. B: H&E score in lung sections. Data are mean±SD. *: P<0.05; ***: P<0.001.

    Figure  5.  Administration of Lor. or Lor./remdesivir blocks MC accumulation

    A: Mock infection. B: BALB/c mice were infected intranasally with SARS-CoV-2 501Y.V2 strain (7.1×104 CCID50). C: Remdesivir (25 mg/kg) was administered (i.p.) at time of infection and used once daily until euthanasia. D, E: In some mice, Lor. (10 mg/kg) was administered (i.p.) 1 day before infection, then continued each day over the course of infection. Lungs were collected at 3 dpi. Toluidine blue staining of lung sections was used to observe MCs and their degranulation. Scale bar: 100 μm.

  • [1] Abdelaziz MM, Khair OA, Devalia JL. 2000. The potential of active metabolites of antihistamines in the management of allergic disease. Allergy, 55(5): 425−434. doi: 10.1034/j.1398-9995.2000.00114.x
    [2] Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, et al. 2021. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. eBioMedicine, 72: 103595. doi: 10.1016/j.ebiom.2021.103595
    [3] Attiq A, Yao LJ, Afzal S, Khan MA. 2021. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. International Immunopharmacology, 101: 108255. doi: 10.1016/j.intimp.2021.108255
    [4] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. 2020. Remdesivir for the treatment of covid-19 - final report. The New England Journal of Medicine, 383(19): 1813−1826. doi: 10.1056/NEJMoa2007764
    [5] Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, et al. 2021. Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clinical Infectious Diseases, 73(11): 2031−2036. doi: 10.1093/cid/ciab536
    [6] Biswas P, Hasan MM, Dey D, Dos Santos Costa AC, Polash SA, Bibi S, et al. 2021. Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. Environmental Science and Pollution Research, 28(42): 59570−59593. doi: 10.1007/s11356-021-16096-3
    [7] Chen NS, Zhou M, Dong X, Qu JM, Gong FY, Han Y, et al. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223): 507−513. doi: 10.1016/S0140-6736(20)30211-7
    [8] Chen T, Fei CY, Chen YP, Sargsyan K, Chang CP, Yuan HS, et al. 2021. Synergistic inhibition of SARS-CoV-2 replication using disulfiram/ebselen and remdesivir. ACS Pharmacology & Translational Science, 4(2): 898−907.
    [9] Da Silva Motta Junior J, Dos Santos Miggiolaro AFR, Nagashima S, De Paula CBV, Baena CP, Scharfstein J, et al. 2020. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Frontiers in Immunology, 11: 574862. doi: 10.3389/fimmu.2020.574862
    [10] Daher J. 2021. Endothelial dysfunction and COVID-19 (Review). Biomedical Reports, 15(6): 102. doi: 10.3892/br.2021.1478
    [11] De Clercq E. 2021. Remdesivir: Quo vadis?. Biochemical Pharmacology, 193: 114800. doi: 10.1016/j.bcp.2021.114800
    [12] Dos Santos Miggiolaro AFR, Da Silva Motta Junior J, De Paula CBV, Nagashima S, Malaquias MAS, Carstens LB, et al. 2020. Covid-19 cytokine storm in pulmonary tissue: Anatomopathological and immunohistochemical findings. Respiratory Medicine Case Reports, 31: 101292. doi: 10.1016/j.rmcr.2020.101292
    [13] Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. 2020. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology, 159(3): 1129−1131.E3. doi: 10.1053/j.gastro.2020.05.053
    [14] Garibaldi BT, Wang KB, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, et al. 2021. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Network Open, 4(3): e213071. doi: 10.1001/jamanetworkopen.2021.3071
    [15] Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, et al. 2020. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Frontiers in Pharmacology, 11: 857. doi: 10.3389/fphar.2020.00857
    [16] Hogan II RB, Hogan III RB, Cannon T, Rappai M, Studdard J, Paul D, et al. 2020. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulmonary Pharmacology & Therapeutics, 63: 101942.
    [17] Huang CL, Huang LX, Wang YM, Li X, Ren LL, Gu XY, et al. 2021. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet, 397(10270): 220−232. doi: 10.1016/S0140-6736(20)32656-8
    [18] Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet, 395(10238): 1695−1704. doi: 10.1016/S0140-6736(20)31042-4
    [19] Iaboni A, Wong N, Betschel SD. 2021. A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma. Journal of Clinical Immunology, 41(5): 923−925. doi: 10.1007/s10875-021-00983-y
    [20] Itoh K, Sakamaki I, Hirota T, Iwasaki H. 2022. Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: a case-series study. Journal of Infection and Chemotherapy, 28(1): 124−127. doi: 10.1016/j.jiac.2021.09.016
    [21] Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, et al. 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 69(9): 1592−1597. doi: 10.1136/gutjnl-2020-321852
    [22] Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. 2021. Baricitinib plus remdesivir for hospitalized adults with covid-19. The New England Journal of Medicine, 384(9): 795−807. doi: 10.1056/NEJMoa2031994
    [23] Komi DEA, Wöhrl S, Bielory L. 2020. Mast cell biology at molecular level: a comprehensive review. Clinical Reviews in Allergy & Immunology, 58(3): 342−365.
    [24] Konkolova E, Dejmek M, Hřebabecký H, Šála M, Böserle J, Nencka R, et al. 2020. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. Antiviral Research, 182: 104899. doi: 10.1016/j.antiviral.2020.104899
    [25] Lam HY, Tergaonkar V, Kumar AP, Ahn KS. 2021. Mast cells: therapeutic targets for COVID-19 and beyond. IUBMB Life, 73(11): 1278−1292. doi: 10.1002/iub.2552
    [26] Mahase E. 2021a. Covid-19: molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ, 375: n2422.
    [27] Mahase E. 2021b. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ, 375: n2713.
    [28] Mahase E. 2021c. Covid-19: UK becomes first country to authorise antiviral molnupiravir. BMJ, 375: n2697.
    [29] Malone RW, Tisdall P, Fremont-Smith P, Liu YF, Huang XP, White KM, et al. 2021. COVID-19: famotidine, histamine, mast cells, and mechanisms. Frontiers in Pharmacology, 12: 633680. doi: 10.3389/fphar.2021.633680
    [30] Marfe G, Perna S, Shukla AK. 2021. Effectiveness of COVID-19 vaccines and their challenges (Review). Experimental and Therapeutic Medicine, 22(6): 1407. doi: 10.3892/etm.2021.10843
    [31] Mather JF, Seip RL, McKay RG. 2020. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. The American Journal of Gastroenterology, 115(10): 1617−1623. doi: 10.14309/ajg.0000000000000832
    [32] Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, et al. 2021. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Molecular Medicine, 13(1): e13426.
    [33] Mouffak S, Shubbar Q, Saleh E, El-Awady R. 2021. Recent advances in management of COVID-19: a review. Biomedicine & Pharmacotherapy, 143: 112107.
    [34] Mukherjee R, Bhattacharya A, Bojkova D, Mehdipour AR, Shin D, Khan KS, et al. 2021. Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. Journal of Biological Chemistry, 297(2): 100925. doi: 10.1016/j.jbc.2021.100925
    [35] Murdaca G, Di Gioacchino M, Greco M, Borro M, Paladin F, Petrarca C, et al. 2021. Basophils and mast cells in COVID-19 pathogenesis. Cells, 10(10): 2754. doi: 10.3390/cells10102754
    [36] Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH III, et al. 2020. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Reports, 32(3): 107940. doi: 10.1016/j.celrep.2020.107940
    [37] Qin C, Zhou LQ, Hu ZW, Zhang SQ, Yang S, Tao Y, et al. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases, 71(15): 762−768. doi: 10.1093/cid/ciaa248
    [38] Rauti R, Shahoha M, Leichtmann-Bardoogo Y, Nasser R, Paz E, Tamir R, et al. 2021. Effect of SARS-CoV-2 proteins on vascular permeability. eLife, 10: e69314. doi: 10.7554/eLife.69314
    [39] Rochwerg B, Agarwal A, Zeng LN, Leo YS, Appiah JA, Agoritsas T, et al. 2020. Remdesivir for severe covid-19: a clinical practice guideline. BMJ, 370: m2924.
    [40] Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. 2021. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Medicine, 47(11): 1258−1270. doi: 10.1007/s00134-021-06507-x
    [41] Rubin D, Chan-Tack K, Farley J, Sherwat A. 2020. FDA approval of remdesivir - a step in the right direction. New England Journal of Medicine, 383(27): 2598−2600. doi: 10.1056/NEJMp2032369
    [42] Schloer S, Brunotte L, Mecate-Zambrano A, Zheng SY, Tang J, Ludwig S, et al. 2021. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. British Journal of Clinical Pharmacology, 178(11): 2339−2350. doi: 10.1111/bph.15418
    [43] Shuai HP, Chan JFW, Yuen TTT, Yoon C, Hu JC, Wen L, et al. 2021. Emerging SARS-CoV-2 variants expand species tropism to murines. eBioMedicine, 73: 103643. doi: 10.1016/j.ebiom.2021.103643
    [44] Slater JW, Zechnich AD, Haxby DG. 1999. Second-generation antihistamines: a comparative review. Drugs, 57(1): 31−47. doi: 10.2165/00003495-199957010-00004
    [45] Song TZ, Zheng HY, Han JB, Jin L, Yang X, Liu FL, et al. 2020. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zoological Research, 41(5): 503−516. doi: 10.24272/j.issn.2095-8137.2020.202
    [46] Stegmann KM, Dickmanns A, Gerber S, Nikolova V, Klemke L, Manzini V, et al. 2021. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Virus Research, 302: 198469. doi: 10.1016/j.virusres.2021.198469
    [47] Tian RR, Yang CX, Zhang M, Feng XL, Luo RH, Duan ZL, et al. 2021. Lower respiratory tract samples are reliable for severe acute respiratory syndrome coronavirus 2 nucleic acid diagnosis and animal model study. Zoological Research, 42(2): 161−169. doi: 10.24272/j.issn.2095-8137.2020.329
    [48] Wang DW, Hu B, Hu C, Zhu FF, Liu X, Zhang J, et al. 2020a. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323(11): 1061−1069. doi: 10.1001/jama.2020.1585
    [49] Wang P, Luo RH, Zhang M, Wang YQ, Song TZ, Tao TT, et al. 2020b. A cross-talk between epithelium and endothelium mediates human alveolar-capillary injury during SARS-CoV-2 infection. Cell Death & Disease, 11(12): 1042.
    [50] Wang YM, Zhang DY, Du GH, Du RH, Zhao JP, Jin Y, et al. 2020c. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236): 1569−1578. doi: 10.1016/S0140-6736(20)31022-9
    [51] Wu ML, Liu FL, Sun J, Li X, He XY, Zheng HY, et al. 2021. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. Signal Transduction and Targeted Therapy, 6(1): 428. doi: 10.1038/s41392-021-00849-0
    [52] Xu L, Yu DD, Ma YH, Yao YL, Luo RH, Feng XL, et al. 2020. COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. Zoological Research, 41(5): 517−526. doi: 10.24272/j.issn.2095-8137.2020.053
    [53] Ye ZW, Yuan SF, Chan JFW, Zhang AJ, Yu CY, Ong CP, et al. 2021. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Emerging Microbes & Infections, 10(1): 291−304.
    [54] Zhou YY, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. 2019. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications, 10(1): 1523. doi: 10.1038/s41467-019-09234-6
  • ZR-2021-469-Supplementary Materials.pdf
  • 加载中
图(5)
计量
  • 文章访问数:  525
  • HTML全文浏览量:  247
  • PDF下载量:  104
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-03-18
  • 录用日期:  2022-04-19
  • 网络出版日期:  2022-04-25
  • 刊出日期:  2022-05-18

目录

    /

    返回文章
    返回